Alnylam Pharmaceuticals (ALNY) News Today $246.58 +2.59 (+1.06%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Leerink Partners Reaffirms Their Hold Rating on Alnylam Pharma (ALNY)December 18 at 5:23 AM | markets.businessinsider.comAtea Pharmaceuticals (NASDAQ:AVIR) & Alnylam Pharmaceuticals (NASDAQ:ALNY) Head-To-Head SurveyDecember 18 at 2:43 AM | americanbankingnews.comCautious Optimism for Tenaya Therapeutics’ TN-201: Early Phase Study Shows Promising Efficacy and SafetyDecember 18 at 12:14 AM | markets.businessinsider.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $298.09 Consensus Target Price from BrokeragesDecember 16 at 3:21 AM | americanbankingnews.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest Down 9.4% in NovemberAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) was the recipient of a large drop in short interest during the month of November. As of November 30th, there was short interest totalling 3,390,000 shares, a drop of 9.4% from the November 15th total of 3,740,000 shares. Based on an average daily volume of 761,800 shares, the days-to-cover ratio is presently 4.4 days.December 15 at 12:01 PM | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by Toronto Dominion BankToronto Dominion Bank raised its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 27.3% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 15,466 shares of the biopharmaceutical company'December 15 at 4:42 AM | marketbeat.comPushkal Garg Sells 1,752 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) StockDecember 14, 2024 | insidertrades.comTidal Investments LLC Has $5.65 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Tidal Investments LLC increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 75.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 20,544 shares of the biopharmaceutical company's stockDecember 14, 2024 | marketbeat.comInsider Selling: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Sells 1,752 Shares of StockAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) CMO Pushkal Garg sold 1,752 shares of the company's stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $251.00, for a total transaction of $439,752.00. Following the completion of the transaction, the chief marketing officer now owns 15,705 shares of the company's stock, valued at $3,941,955. This trade represents a 10.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.December 13, 2024 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by Geode Capital Management LLCGeode Capital Management LLC lifted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 3.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,147,203 shares of the biopharmaceuDecember 13, 2024 | marketbeat.comKovitz Investment Group Partners LLC Invests $669,000 in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Kovitz Investment Group Partners LLC acquired a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 2,431 shares of the biopharmaceutical company's stocDecember 13, 2024 | marketbeat.comRegeneron’s R&D approach scores dual wins against Alexion’s Ultomiris and in lymphomaDecember 12, 2024 | finance.yahoo.comPublic Employees Retirement System of Ohio Sells 3,275 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Public Employees Retirement System of Ohio lowered its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 6.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 48,437 shares ofDecember 12, 2024 | marketbeat.comNomura Asset Management Co. Ltd. Grows Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Nomura Asset Management Co. Ltd. raised its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 7.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 85,445 shares of the biopharDecember 11, 2024 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of "Moderate Buy" from BrokeragesAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the twenty-four ratings firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, five have given a hold rating and eDecember 11, 2024 | marketbeat.comGroupama Asset Managment Has $418,000 Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Groupama Asset Managment lessened its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 0.2% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,521,385 shares of the biopharmaceutical company's stock afterDecember 10, 2024 | marketbeat.comREGN : Poze-Cemdi Combo In Phase 3 Result Shows Superior Hemolysis Control In PNH Vs. RavulizumabDecember 8, 2024 | markets.businessinsider.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Holdings Lowered by Two Sigma Advisers LPTwo Sigma Advisers LP lowered its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 60.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 103,100 shares of the biopharmaceutical compDecember 8, 2024 | marketbeat.comAlnylam Pharma (ALNY) Gets a Buy from Piper SandlerDecember 6, 2024 | markets.businessinsider.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Polar Asset Management Partners Inc.Polar Asset Management Partners Inc. cut its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 41.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,900 sharesDecember 6, 2024 | marketbeat.comJanus Henderson Group PLC Decreases Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Janus Henderson Group PLC cut its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 12.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 219,337 shares of the biopharmaceutical company's sDecember 6, 2024 | marketbeat.comHighTower Advisors LLC Reduces Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)HighTower Advisors LLC cut its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 7.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 115,790 shares of the biopharmaceutical company's stock after selling 9,251 sharesDecember 6, 2024 | marketbeat.comRoyal London Asset Management Ltd. Lowers Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Royal London Asset Management Ltd. trimmed its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 0.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 279,750 shares of the biopharmaceutical company's stock afterDecember 5, 2024 | marketbeat.comInvestment Management Corp of Ontario Grows Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Investment Management Corp of Ontario increased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 153.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,059 shares of the biopharmaceuDecember 5, 2024 | marketbeat.comParkman Healthcare Partners LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Parkman Healthcare Partners LLC bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 25,485 shares of the biopharmaceutical company's stock, valueDecember 4, 2024 | marketbeat.comErste Asset Management GmbH Makes New $4.54 Million Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Erste Asset Management GmbH bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 16,510 shares of the biopharmaceutical compDecember 3, 2024 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by BRITISH COLUMBIA INVESTMENT MANAGEMENT CorpBRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lessened its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 12.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 21,108December 3, 2024 | marketbeat.comBridgewater Associates LP Purchases New Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Bridgewater Associates LP bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 2,002 shares of the biopharmaceutical company's stock, valued atDecember 3, 2024 | marketbeat.comPDT Partners LLC Sells 10,800 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)PDT Partners LLC reduced its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 75.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,484 shares of the biopharmaceutical company's stock aDecember 2, 2024 | marketbeat.comBellevue Group AG Sells 110,739 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Bellevue Group AG decreased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 12.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 809,095 shares of the biopharmaceutical companDecember 1, 2024 | marketbeat.comCerity Partners LLC Increases Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Cerity Partners LLC grew its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 133.6% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 13,019 shares of the biopharmaceutical company's stock after acquiring an additionalNovember 30, 2024 | marketbeat.comEventide Asset Management LLC Has $61.70 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Eventide Asset Management LLC boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 157.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 224,333 shares of the biopharmaceutical company's stock after buyinNovember 29, 2024 | marketbeat.comSuvretta Capital Management LLC Has $3.80 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Suvretta Capital Management LLC reduced its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 63.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 13,824 shares of the biopharmNovember 29, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Sells 137,655 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)The Manufacturers Life Insurance Company lessened its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 41.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 191,382 shares of the biopharmaceutical company's stock after sellinNovember 29, 2024 | marketbeat.comAlnylam Pharmaceuticals: Promising Advancements in Alzheimer’s Treatment with RNA Interference TherapeuticsNovember 28, 2024 | markets.businessinsider.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Tolga Tanguler Sells 1,469 SharesNovember 28, 2024 | insidertrades.comOpinion | A Short Lesson in Drug CompetitionNovember 28, 2024 | msn.comAlnylam Pharma’s Regulatory Challenges and Market Uncertainty Lead to Hold RatingNovember 28, 2024 | markets.businessinsider.comAlnylam Pharma (ALNY) Gets a Buy from RBC CapitalNovember 28, 2024 | markets.businessinsider.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Penserra Capital Management LLCPenserra Capital Management LLC lowered its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 77.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,413 shares of the biopharmaceutical company'sNovember 28, 2024 | marketbeat.comAlnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare ConferenceNovember 27, 2024 | businesswire.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by Swedbank ABSwedbank AB increased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 160.3% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 53,729 shares of the biopharmaceutical company's stocNovember 27, 2024 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stake Boosted by Algert Global LLCAlgert Global LLC boosted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 401.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,825 shares of the biopharmaceutical comNovember 27, 2024 | marketbeat.comHemophilia B Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Pipeline, Epidemiology and Companies by DelveInsightNovember 27, 2024 | theglobeandmail.comScotiabank Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)November 26, 2024 | markets.businessinsider.comAlnylam Pharmaceuticals: Strategic Positioning and Growth Opportunities Reinforce Buy Rating Amidst Competitive ATTR-CM MarketNovember 26, 2024 | markets.businessinsider.comBridgeBio Soars After Drug Gets Nod in Rare Heart ConditionNovember 26, 2024 | msn.comCheck Out What Whales Are Doing With ALNYNovember 26, 2024 | benzinga.comFDA accepts Alnylam’s sNDA for vutrisiran for ATTR-CM treatmentNovember 26, 2024 | markets.businessinsider.comAlnylam Pharma: Strong Buy Rating Backed by Regulatory Success and Diverse RNAi PortfolioNovember 26, 2024 | markets.businessinsider.com Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Email Address AI Crypto Tool Could Send One Coin SOARING… (Ad)The #1 AI Coin to Buy Rapid growth predicted for little-known AI crypto project Discover our #1 crypto pick before it's too late. ALNY Media Mentions By Week ALNY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALNY News Sentiment▼0.990.69▲Average Medical News Sentiment ALNY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALNY Articles This Week▼1511▲ALNY Articles Average Week Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Vertex Pharmaceuticals News Gilead Sciences News Regeneron Pharmaceuticals News Biogen News United Therapeutics News Neurocrine Biosciences News Incyte News BioMarin Pharmaceutical News Exact Sciences News Exelixis News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALNY) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
